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Background: Flavonoids, which have been identified in a variety of plants, have been demonstrated to elicit
beneficial effects on memory. Some studies have reported that flavonoids derived from Erythrina plants can provide
such beneficial effects on memory. The aim of this study was to identify the flavonoids present in the stem bark
crude extract of Erythrina falcata (CE) and to perform a bioactivity-guided study on conditioned fear memory.
Methods: The secondary metabolites of CE were identified by high performance liquid chromatography combined
with a diode array detector, electrospray ionization tandem mass spectrometry (HPLC-DAD-ESI/MSn) and nuclear
magnetic resonance (NMR). The buthanolic fraction (BuF) was obtained by partitioning. Subfractions from BuF
(BuF1 – BuF6) and fraction flavonoidic (FfA and FfB) were obtained by flash chromatography. The BuF3 and BuF4
fractions were used for the isolation of flavonoids, which was performed using HPLC-PAD. The isolated substances
were quantified by HPLC-DAD and their structures were confirmed by nuclear magnetic resonance (NMR). The
activities of CE and the subfractions were monitored using a one-trial, step-down inhibitory avoidance (IA) task
to identify the effects of these substances on the acquisition and extinction of conditioned fear in rats.
Results: Six subclasses of flavonoids were identified for the first time in CE. According to our behavioral data,
CE, BuF, BuF3 and BuF4, the flavonoidic fractions, vitexin, isovitexin and 6-C-glycoside-diosmetin improved the
acquisition of fear memory. Rats treated with BuF, BuF3 and BuF4 were particularly resistant to extinction. Nevertheless,
rats treated with FfA and FfB, vitexin, isovitexin and 6-C-glycoside-diosmetin exhibited gradual reduction in conditioned
fear response during the extinction retest session, which was measured at 48 to 480 h after conditioning.
Conclusions: Our results demonstrate that vitexin, isovitexin and diosmetin-6-C-glucoside and flavonoidic fractions
resulted in a significant retention of fear memory but did not prevent the extinction of fear memory. These results
further substantiate that the treatment with pure flavonoids or flavanoid-rich fractions might represent potential
therapeutic approaches for the treatment of neurocognitive disorders, improvement of memory acquisition and
spontaneous recovery of fear.
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Despite remarkable progress that has been made on the
understanding of how the brain acquires, stores, and re-
trieves information, modest progress has been made in
treating cognitive deficit. The loss of memory can causes
a range of disabilities, which can significantly impact
daily performance in terms of simple tasks and difficulty* Correspondence: smcerutti@unifesp.br
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article, unless otherwise stated.in making choices, potentially resulting in poor judg-
ment or socially inappropriate behavior. Therefore, the
development of new therapeutic drugs for the treatment
of cognitive impairment remains a major focus of
neuroscience.
Accumulating evidence has shown that the herbs repre-
sent a promising source of novel therapeutic agents.
Recent studies from our laboratory have shown that
short- and long-term treatment with a standardized,
flavanoid-rich extract of Ginkgo biloba (EGb) can improve
conditioned-fear memory. However, unlike diazepam,tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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treatment with EGb did not cause deficits in the acquisi-
tion of a conditioned emotional response (CER) [1,2].
Conversely, Erythrina velutina, a plant that is rich in
alkaloids and flavonoids, is widely used for anxiolytic
purposes. At low doses, it impairs the acquisition of fear
conditioning in inhibitory avoidance task, whereas at high
doses, it predominantly elicits sedative and neuromuscular
blocking effects [3].
Erythrina (Fabaceae family) is a genus of approxi-
mately 130 species from tropical and subtropical regions
worldwide. It is widely distributed in south and south-
eastern Brazil, north Argentine and Paraguay, south
Bolivia and Peru [4]. Erythrina species are known to
produce alkaloids [5-9], terpenes [10] and flavonoids
[7,8,10-15], and their stem bark and leaves are commonly
used to make teas (infusion or decoction) that are believed
that to exhibit tranquilizing and anti-anxiety properties
[16,17]. Based on their common use in folk medicine,
most research on the genus has involved isolating and
characterizing their alkaloid constituents. Information
regarding the flavonoids derived from Erythrina species,
as well as their effects on the central nervous system,
remains limited. Previous studies have suggested that
phytochemicals, particularly flavonoids, might modulate
protein and lipid kinase signaling pathways [1,2,18-21].
Further, polyphenols have been associated with a reduced
risk of the development of dementia [22].
Flavonoids represent a large family of compounds that
are synthesized by plants and that comprise 15 carbons
with two aromatic rings connected by a three-carbon
bridge (C6-C3-C6). Naturally occurring anxiolytic flavo-
noids were first described in 1990s [23-26]. Flavonoids
have been investigated using in vivo models, where their
effects on the central nervous system (CNS) have estab-
lished. More recently their antioxidant activity, which
are attributed to their ability to inhibit the production of
free radicals, and their neuroprotective effects were found
to be related. Moreover, there has been intense interest in
the potential of flavonoids to modulate neuronal function
and to improve memory [22], as well as their activation of
microglia and astrocytes that might shape synaptic
plasticity [27].
Hence, the isolation and characterization of the active
constituents of crude plant extracts can offer great
advantages and provide opportunities for new drug dis-
coveries. In this sense, it is important elucidate which
constituents contained within the crude extract of the
Erythrina falcata (E.falcata) contribute directly or indir-
ectly to its bioactivity. To elucidate the effects of acute
treatment with stem bark crude extract of Erythrina fal-
cata (CE) or of its secondary metabolites on conditioned-
fear memory, we employed a one-way inhibitory avoidance
learning (IA) task, which has been previously used to assessfear memory in rodents that are sensitive to anxiolytic
drugs.
Memory is considered to be a process that includes
acquisition, consolidation and retrieval. In fear-condi-
tioned memory, acquisition refers to the process in which
an association between a neutral conditional stimulus (CS)
and an aversive unconditional stimulus (US) is formed
through the pairing of the CS with the US. Consolidation
refers to a progressive, time-dependent stabilization pro-
cess, which transforms short-term memories into relatively
permanent, long-term memories. Memory retrieval is char-
acterized as the subsequent recovery of events or informa-
tion from the past, which have been previously stored
within specific neural systems. During the retrieval process,
two opposite processes, reconsolidation and extinct, are
initiated, and the memories become labile and can be
affected by pharmacological manipulations at different
stages of this process [28]. The effects of flavonoid-rich
plants and pure flavonoids on memory have been shown
in rodents.
In this study, a monitored fractionation study was used
to identify the effects of isolated pure flavonoids, as well
as of flavonoidic fractions, from crude extracts of E. fal-
cata on the acquisition and extinction of conditioned fear
in rats.
Methods
The extraction, fractionation, isolation and characterization
of bioactive compounds from crude extracts of E. falcata
Chemicals Reagents
Methanol (HPLC grade) and dimethyl sulfoxide-d9 (99.8%)
were obtained from Merck (Darmstadt, Germany). Formic
acid, ethanol and n-buthanol were obtained from Synth
(Diadema, Brazil). Water was produced in our laboratory
(Milli-Q Water Purification System, Millipore). Vitexin and
isovitexin standards (99.99%) were purchased from Sigma-
Aldrich (São Paulo, Brazil).
Plant material
The stem bark of E. falcata plants was collected in
October 2009 in Colombo, Paraná, Brazil. The samples
were registered as number 173 and stored in the herb-
arium of the National Center Research of Forestry –
CNPF, at the Brazilian Agricultural Research Corporation
(EMBRAPA), Brazil.
The preparation of the extract and the monitored
fractionation and identification of its constituents
The stem bark (1 Kg) was extracted by percolation with
EtOH/H2O (70:30) at room temperature for 1 month.
The extract was concentrated into a small volume using
a rotatory evaporator and then freeze-dried to produce a
crude extract (CE, 100 g). The CE (50 g) was suspen-
ded in H2O/MeOH (2:1) and partitioned using nBuOH
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nolic total fraction (BuF) and an aqueous fraction (AF).
These fractions were concentrated into a small volume at
37°C using a rotatory evaporator and then freeze-dried,
yielding 13.48 and 32.68 g of BuF and AF, respectively.
Part of the BuF (3.0 g) was further fractionated by flash
chromatography on a C18 (40 μm, APD, 60 Å, J.T. Baker,
USA) column (2.5 cm × 40 cm), using step gradient
elution of H2O to MeOH (1:0; 8:2; 6:4; 4:6; 2:8; 0:1). Six
fractions (90 mL each) were collected (BuF1- BuF6).
Another portion of BuF (5 g) was fractionated again by
flash chromatography on a C18 (40 μm, APD, 60 Å, J.T.
Baker, USA) columm (4.5 cm × 40 cm), under the same
conditions, subsequently yielding 15 fractions (50 mL
each, Ff1A-Ff1C, Ff2A-Ff2C, Ff3A-Ff3C, Ff4A-Ff4C
and Ff5A-Ff5C) to produce a flavonoid-enriched fraction
(Figure 1).
HPLC-DAD analysis was performed using a Shimadzu
apparatus equipped with a DGU-20A5 degasser, two
LC-20AT pumps, a CBM-20A controller, a SIL-20A3
autosampler, a CT0-20A oven column and a SPD-M20A
diode array detector (DAD, Shimadzu (Kyoto, Japan). The
studies were conducted on a C18 Luna® column (250 mm ×
4.60 mm, 5 μm) (Phenomenex, Torrance, CA, USA). The
mobile phase consisted of 0.1% aqueous formic acid (A)
and methanol (B). A gradient of A/B (95:5 to 1:1, v/v in
50 min) was used. UV spectra were achieved from 200–
400 nm, and the chromatogram registered at 254 nm. The
flow rate was maintained at 1.0 mL.min−1, sample con-
centration was 1 mg.mL−1 and the injection volume was
20 μL. Analysis of the data was performed using LC
Solution® 1.23 SP1 software (Shimadzu, Kyoto, Japan). The
classes of the compounds were identified according to
their UV spectra and retention time. After the chromato-
graphic profile analyses, all of the CE, BuF, subfractions
(BuF1-Buf6), FfA and FfB samples were subjected to
evaluation of their bioactivities using a one-trial, step-
down avoidance inhibitory (IA) test (Figure 2).
Our behavioral results indicate that the BuF3 and
BuF4 subfractions can modulate the retention of fear
memory. Consequently, fractions BuF3 (0.45 g) and BuF4
(0.31 g) were subjected to the further isolation of flavo-
noids, which was performed using a preparative HPLC-
PAD (CBM-20A, Shimadzu, Kyoto, Japan) equipped withFigure 1 A schematic of the process used for the preparation of Erythria DGU-20A5 degasser, two LC-6 AD pumps, a CBM-20A
controller, a SIL-10AF autosampler, a SPD-M20A photo-
diode array detector (PAD) and a C18 Luna® column
(Phenomenex, Torrance, CA, USA) (150 mm × 21.20 mm,
5 μm, 100 Å). The mobile phase consisted of 0.1% aqueous
formic acid (A) and methanol (B). An isocratic elution
method of A/B was used for BuF3 (70:30, v/v) and for
BuF4 (64:36, v/v), both at a flow-rate of 5 mL.min−1. The
sample concentrations were 10 mg.mL−1, injection vol-
umes were 2 mL and detection was monitored at 254 nm.
The compounds were collected according to their UV
spectrum profiles and tR (retention time) (Figure 1C).
BuF3 yielded compound 1 (11.8 mg, tR 19.36 min) and
BuF4 yielded compounds 3 (10.8 mg, tR 22.76 min), 4
(8.1 mg, tR 23.66 min) and 5 (6.6 mg, tR 23.80 min). The
activity of these compounds was also evaluated.
The identification of the isolated compounds was based
on mass spectrometry (MS) and nuclear magnetic reson-
ance (NMR) analyses. The 1H spectra were recorded using
a Varian INOVA 500 spectrometer with dimethylsulfoxide-
d9 as a solvent. The
1H NMR spectra at 500 MHz and
the 13C NMR spectra at 250 MHz were expressed as δ
ppm, with reference to TMS, and the coupling constants
(J) were expressed as Hertz (Hz). The results obtained
were compared with NMR spectra that have been previ-
ously published.
The CE was additionally analyzed by online high per-
formance liquid chromatography combined with electro-
spray ionization tandem mass spectrometry (HPLC-ESI/
MSn) using a Thermo LCQ Fleet System mass spectrom-
eter (Thermo Scientific, San Diego, CA, USA) equipped
with an electrospray interface (ESI) and HPLC (model
Accela, Thermo Scientific). CE separation was perfor-
med using a Luna® C18 column (250 mm × 4.60 mm;
Phenomenex, Torrance, CA, USA) at room temperature.
The mobile phase consisted of 0.1% aqueous formic acid
water (A) and methanol (B). A gradient elution method of
A/B (95:5 to 1:1, v/v) was used over 50 min. Ultraviolet
(DAD) detection was performed at 254 nm, the flow rate
was kept at 0.8 mL/min, the sample concentrations were
1 mg.mL−1 and the injection volumes were 10 μL. The
column effluents were analyzed by ESIMS in negative ion
mode in the mass-to-charge ratio (m/z) range of 50–2000,
with a scan time of 0.3 s in the centroid mode. The ESIna falcata extracts and subsequent bioactivity-guided fractionation.
Figure 2 A schematic of the experimental procedure for the one-trial, step-down avoidance inhibitory task (IA) and drug administration
schedule, which was the same for all of the animal groups except for the CS group. The rats evaluated by the IA task were subjected to one
training session (a 2-s, 0.5-mA footshock (US) associated with a context (CS)). The animals were subjected to five retention test sessions (trials) of IA
tasks, and the step-down latencies were measured. No footshock was administered in the test sessions. The interval between trials T1, T2 and T3 was
24 h. T4 and T5 comprised 240- and 480-h intervals, respectively.
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30 psi; drying gas, 60 L.min−1; drying temperature, 280°C;
capillary voltage, 4000 V; nitrogen as collision gas and col-
lision energy at 1 V. The data were acquired in MS and
MSn scanning modes. The CE was dissolved in H2O:
MeOH (1:1 v/v) and infused directly via a syringe pump
(flow rate 5 μL.min−1) in the ESI source. The data were
analyzed using Xcalibur 2.0 Software® (Thermo Scientific).
The nomenclature ascribed to the fragmented ions for
the glycoconjugates were previously proposed by Domon
and Costello [29].
Quantitative analysis of flavonoids
The flavonoids were quantified by HPLC-DAD on a
Luna® C18 column (Phenomenex, Torrance, CA, USA)
(250 mm × 4.60 mm, 5 μm). The mobile phase consisted
of 0.1% aqueous formic acid (A) and methanol (B). An
isocratic elution method of A/B (64:36, v/v) was used
over 50 min. Detection was performed at 254 nm, the
flow rate was maintained at 1 mL.min−1, sample concen-
trations were 1 mg.mL−1 and the injection volumes were
10 μL. Analytical curves were constructed using solutions
of standards from compounds 1, 3, 4 and 5 (1 mg.mL−1of
each compound in methanol/water 80:20), reaching con-
centrations within a range of 100.0 to 1000 mg.mL−1.
Sample peak areas were integrated at 254 nm. All of the
procedures were performed in triplicate.
Monitored fractionation by one-trial step-down inhibitory
avoidance (IA) task
Subjects
A total of the 200 adult male Wistar rats (±250-300 g)
with 3 month age were obtained from the CEDEME
(Center for Development of Experimental Medicine andBiology, Federal University of Sao Paulo, SP, Brazil). The
rats were housed five animals/cages. For 15 days, the ani-
mals had free access to food and water under a 12 h:12 h
dark:light cycle (lights on at 6:00 to 8:00 h.) with con-
trolled temperatures (21°C ± 2°C) and relative humidity
(53 ± 2). These conditions were maintained during the en-
tire experimental period. One minute prior to each experi-
mental session, each rat was placed into an individual cage
for transportation to the testing room. All of the proce-
dures for the manipulation of animals were consistent
with the Ethical Principles in Animal Research adopted by
the Brazilian College for Animal Experimentation (COBEA)
and as suggested by the APA Guidelines for Ethical
Conduct in the Care and Use of Animals. Filed under
number of 0819/10, Research Ethics Committee.
Experimental protocol
The rats were randomly assigned into 20 groups (n = 10/
group) as follows: conditional stimulus group, no-footshock
group (CS), negative control (12% Tween®80), positive
control (4 mg.Kg−1 Diazepam), crude extract of Erythrina
falcata (CE) (250 mg.Kg−1CE and 500 mg.Kg−1CE), BuF
(145 mg.Kg−1), subfractions (20 mg.Kg−1BuF1, 16 mg.Kg−1
BuF2, 21 mg.Kg−1BuF3, 45 mg.Kg−1BuF4, 13 mg.Kg−1
BuF5 and 27 mg.Kg−1 BuF6), vicenin-2 (0.1 mg.Kg−1,
0.3 mg.Kg−1, 1.0 mg.Kg−1 and 10.0 mg.Kg−1), vitexin
(0.1 mg.Kg−1 and 0.25 mg.Kg−1), isovitexin (0.1 mg.Kg−1
and 0.25 mg.Kg−1), 0.1 mg.Kg−1 6-C-glycoside-diosme-
tin, fraction flavonoidic/Ff (0.65 mg.Kg−1 FfB and 0.90 mg.
Kg−1 FfA).
Systemic administration
All of the substances were administered orally via gastric
tube to ensure complete administration at 30 min before
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dissolved in a 12% Tween®80 solution. Diazepam was
purchased from Hoffman-La Roche (Brazil), and the
dose of Diazepam used in this study was based on the
earlier studies conducted in our laboratory [1,2]. The dose
of CE used in this study was based on earlier studies
conducted in our laboratory (manuscript in preparation).
The buthanolic fraction (BuF), subfractions (BuF1-BuF6),
vicenin-2, vitexin, isovitexin, 6-C-glycoside-diosmetin, and
the flavonoid fractions FfA and FfB were administered at a
rate of 500 mg.Kg−1 CE. The CE, subfractions and 12%
Tween®80 were administered at 30 min prior to the train-
ing session.One-trial, step-down avoidance inhibitory
Behavior apparatus
The one-trial, step-down avoidance inhibitory (IA) appar-
atus consisted of a white wood box (50 × 25 × 25 cm), the
floor of which consisted of parallel 1.0-mm diameter
stainless steel bars spaced at 1.0 cm apart. The left end of
the floor was covered by a 7-cm wide, 2.5-cm high wood
platform [30-32].Behavioral procedure
The rats were fear-conditioned in an IA chamber. The
animals were subjected to one training session (Tr) and
5 test sessions (T1, T2, T3, T4 and T5). All of the groups
were subjected to treatments with different substances
prior to the Tr session as described below, with the
exception of the CS group. After each experimental
session, the animals were returned to their home cages
(Figure 2).Adaptation session (1st day)
The animals were gently placed onto the platform facing
the left rear corner of the training box, and during a
180- sec period, the animals explored the box (condi-
tioned stimulus - CS). After this period, the animals were
returned to their home cages.Training session (2nd day)
The rats were placed onto the platform as during
adaptation session. When they stepped down and placed
all four paws onto the grid, they received a 0.5-mA, 2-s
scrambled foot shock (unconditioned stimulus - US).
The latency to step-down was measured. After the foot-
shock, the animals were returned to their home cage.
This procedure was performed on all of the animals,
except for the CS group, which did not receive a foot-
shock. The rats were then tested for retention 24, 48, 72,
240 and 480 h later.Test session/ acquisition/ T1 (3rd day)
The rats were tested for retention of fear memory at
24 h (T1) and the step-down latency was used as a meas-
ure of retention (to a maximum of 300 s). During the test
sessions, no footshocks were administered.
Test sessions/extinction T2-T5 (4th, 5th, 10th and 21st days)
The animals were subjected to five retention test session
(trials) in an IA task, and step-down latencies were mea-
sured. No footshock was administered during these tests
sessions. The interval between trials T1, T2 and T3 was
24 h. The endpoints of T4 and T5 were designated as
240 and 480 h, respectively, after training.
Data analysis and statistical procedures
For the Training (Tr) and Test 1 (T1) sessions, the data are
reported as mean values (±SEM) of latency to step-down
and were analyzed using one-way analysis of variance
(ANOVA) followed by Bonferroni’s Multiple Comparison
Test. For each rat was measured by differences in test-
training session latencies (dL-mean), where dL-mean =
T-Tr latency. Comparisons among dL-mean values were
analyzed by two-way analysis of variance (ANOVA) fol-
lowed by Dunnett’s Multiple Comparison. To test the ef-
fects of each group and session, as well as the interaction
between them, two fixed factors (group and session), one
random factor (rat) and repeated measurement of the
sessions were considered. All of the statistical analyses
were performed using the GraphPad Prism statistics pro-
gram (Graph Pad 6.0 Software®, San Diego, CA, USA).
Differences of the P < 0.05 level were considered statisti-
cally significant.
Results
Identification of the secondary metabolites from crude
extract of E. falcata
The chromatographic profiles of the crude extract of E.
falcata (CE) stem bark recorded at 254 nm are shown in
Figure 3A. The HPLC/UV trace revealed 4 major peaks
and several minor peaks. Structural elucidation was based
on a combination of UV, NMR and MS data.
The chromatographic and spectroscopic data of the
major and minor peaks of the CE are summarized in
Figure 3B, and their structures/fragmentation dates are
shown in Figure 4. The UV spectra obtained from the
main peaks (1 to 6) observed in the HPLC-DAD analysis
reflected a predominance of flavones within these ex-
tracts (Figure 3C). The molecular masses of the com-
pounds examined were obtained from the MS data, and
these identifications were based on the quasimolecular
ion [M-H]− and MS2 spectra. The assignment of the
NMR signals was based on the published chemical shift
values.
Figure 3 HPLC-DAD-ESI/MSn. analysis of crude extracts (CEs) from the roots of Erythrina falcata using a C18 Luna column (A, B). The
chromatogram was recorded at 254 nm (A) and the TIC was in negative mode (B). The UV spectra of compounds 1–6 (C).
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271 nm, Figure 3C1) that is characteristic of a flavone
skeleton [33] and exhibited a quasimolecular ion ([M-H]−)
at m/z 593, yielding secondary fragments at m/z 575([M-
H]− -18), m/z 515 ([0,4Xa]
−; [M-H]− -60), m/z 503 ([0,3Xa]
−;
[M-H]− -90), m/z 473 ([0,2Xa]
−; [M-H]− -120), m/z 455
([0,4Xb]
−; [M-H]− -128), m/z 413 ([0,3Xb]
−; [M-H]− -180),
m/z 383 ([0,4Xb +
0,2Xa]
−; [M-H]− -180), m/z 353 ([0,2Xb]
−;
[M-H]− -240), and m/z 325 ([1,5Xb]
−; [M-H]− 2x 134)
(Figure 4A). This fragmentation pattern is consistent
with a 6,8-C-dihexoseflavone and molecular formula
C27H30O15. This compound was isolated (Figure 4A)as white crystals. Its 1H NMR spectrum (Table 1) in
(DMSO-d6) exhibited one aromatic singlet at δ 6.78,
assigned to H-3, indicating that the aglycone moiety
had substituted C-6 and C-8. The broad singlet at δ
13.7 was attributed to the -OH groups, which form
hydrogen bonds. The signal at 6.91 (d, J = 8.0 Hz) and
8.02 (d, J = 8.0 Hz) indicated that ring B contains a para-
hydroxy group (4′-OH). The carbon signals belonged
to the two sugars, confirming that this compound is
C-diglucoside flavone. The sites of the sugar linkage
to the aglycone were considered to be at positions C-6
and C-8 because the C-8 and C-6 signals appeared at δ
Figure 4 MS2 spectra of deprotonated molecules of crude extracts (CEs) from the roots of Erythrina falcata using a C18 Luna column
as follows: (A) vicenin-2 [M-H]− at m/z 593 (1), (B) vicenin-1 [M-H]− at m/z 563 (2), (C) vitexin [M-H]− at m/z 431 (3), (D) isovitexin [M-H]−
at m/z 431 (4), (E) 6-C-glycoside diosmetin [M-H]− at m/z 461 (5) and (F) apigenin [M-H]− at m/z 269 (6). Fragment ions used as structural
markers are indicated by arrows.
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confirmed by the absence of H-6 and H-8 in the 1H NMR
spectrum. The spectral data (Table 1) obtained were simi-
lar to the reported ones [34,35], confirming the iden-
tification of compound 1 as 6,8-di-C-β-D-glucopyranoside
(vicenin-2).
Compound 2 also exhibited a UV spectrum (λmax = 332,
271 nm, Figure 3C2) that was characteristic of a flavone.
In addition, it exhibited a [M-H]− at m/z 563 and
MS2 ions at m/z 503([0,3Xb]
−; [M-H]− -60), m/z 473
([0,3Xa]
−; [M-H]− -90), m/z 383 ([0,3Xa and
0,2Xb]
−;
[M-H]− -180), m/z 353([0,2Xa and
0,2Xb]
−; [M-H]− -180)
(Figure 4B). This compound was identified as 6-C-β-
D-glucopyranosyl-8-C-β-D-xylopyranosyl-4′,5,7-trihy-
droxyflavone, which is commonly known as vicenin-1
(C26H28O14) [36].
Compound 3 (λmax = 269, 235 nm, Figure 3C3) was
isolated as yellow crystals and exhibited a [M-H]− at m/z
431 and MS2 ions at m/z 311 ([0,2X]−; [M-H]− -120), and
m/z 341 ([0,3X]−; [M-H]− -90), (Figure 4C). The 1H
NMR spectrum (Table 1) showed resonances for two
sets of doublets at δH 8.02 and 6.89, which were
assigned to H-2′, 6′ and H-3, respectively. In addition,
two singlets at δ 6.77 and δ 6.26 were assigned to H-3
and H-6, respectively. These data indicated that the agly-
cone moiety was analogous to apigenin. The broad sing-
let at δ 13.16 was attributed to the -OH group, which
forms hydrogen bonds. The presence of an anomeric
proton at δ 6.2 suggested that this compound is a C8-
glucosil flavone [37,38]. Comparing the spectroscopic
data of compound 3 with the reported ones confirmed
its structure to be 5, 7, 4′-trihydroxyflavone- 8-C-β-D-glucopyranoside, which is commonly known as vitexin
(C21H20O10) [37,38].
Compound 4 (λmax = 335, 271 nm, Figure 3C4) was
isolated as yellow crystals (Figure 3C4). The quasimole-
cular ion [M-H]− was observed at m/z 431 and its MS2
fragments at m/z 413 ([M-H]− -18), m/z 341 ([0,3X]−;
[M-H]− -90) and m/z 311 ([0,2X ]−; [M-H]− -120) are
similar to compound 3 (Figure 4D). The 1H NMR spec-
trum (Table 1) of this compound showed one singlet at δ
6.75, which was attributable to H-3, two signals corre-
sponding to the ring B at δ 6.92 (d, J = 9.0 Hz and 3.0 Hz;
H-5′ and H-3′) and 7.91 (d, J = 9.5 Hz; H-2′ and H-6′)
indicating the presence of a 4′-OH group. The broad sing-
let at δ 13.54 was attributed to the -OH groups, which
form hydrogen bonds. The signal at δ 6.26 (singlet) was
attributed to H-8 of ring A, which is characteristic of a C-
glycoside. The anomeric proton signals for the isovitexin
appeared at δ 4.69 (d, J = 9.5 Hz; H-1″). The presence of
an anomeric proton at δ 4.69 (d, J = 9.5 Hz; H-1″) at-
tached to carbon at δ73.66 suggested that compound 4 is
a C-glucoside flavone. The sites of the sugar linkage to the
aglycone were considered to be at the C-6 positions, due
to the presence of a quaternary C-6- signal at δ 109.29
and a protonated C-8 signal at δ94.32. Comparing the
spectroscopic data of compound 3 with published spectra
[39-41] confirmed its structure to be 5,7,4′-trihydroxy-
flavone- 6-C-β-D-glucopyranoside, which is commonly
known as isovitexin (C21H20O10).
Compound 5 (λmax = 342, 270 nm, Figure 3C5) exhib-
ited a [M-H]− ion at m/z 461 and MS2 ions at m/z 371
([0,3X]−; [M-H]− -90), m/z 383 ([0,4X]−; [M-H]− -60-18),
m/z 341 ([0,2X]−; [M-H]− -120) (Figure 4E). This compound
Table 1 NMR Data for Compounds 1, 3–5 (DMSO-d6, 500 MHz)
Position
1 3 4 5
1H NMR (δH)
13C NMR (δC)
1H NMR (δH)
13C NMR (δC)
1H NMR (δH)
13C NMR (δC)
1H NMR (δH)
13C NMR (δC)
2 ————————— 163.9 ————————— ————————— ————————— 163.3 ————————— 163.3
3 6.78 [1H, s] 102.5 6.77 [1H, s] ————————— 6.75 [1H, s] 103.8 6.86 [1H, s] 103.1
4 ————————— 182.2 ————————— ————————— ————————— 182.4 ————————— 181.7
5 ————————— 161.2 13.16 [OH, s] ————————— 13.54 [OH, s] 161.0 8.37 [OH, s] 161.5
6 ————————— 107.6 6.26 [1H, s] ————————— ————————— 109.2 ————————— —————————
7 ————————— 161.3 ————————— ————————— ————————— 163.9 ————————— 163.6
8 ————————— 105.3 ————————— ————————— 6.49 [1H, s] 94.32 6.51 [1H, s] 93.4
9 ————————— 155.1 ————————— ————————— ————————— ————————— ————————— —————————
1′ ————————— 121.5 ————————— ————————— ————————— 121.4 ————————— 123.0
2′ , 6′ 8.02 [2H, d, (6.5)] 129,0 8.03 [2H, d,(10.0)] ————————— 7.91 [2H, d, (8.5)] 128.9 7.55 [2H, d, (8.0)] 109.8
3′ , 5′ 6.91 [2H, d, (8.5)] 115.9 6.89 [2H, d, (10.0)] ————————— 6.92 [2H, d, (9.0)] 116.5 6.94 [2H, d, (8.0)] 115.4
4′ ————————— 161.3 ————————— ————————— ————————— 161.2 3.89 [OCH3] 55.6
1″ 4.71 [1H, d, (9)] 73.4 4.69 [1H, d, (9.5)] ————————— 4.59 [1H, d, (10.0)] 73.6 4.60 [1H, d, (9.5)] 72.9
2″ 3.38 - 3.80 71.0 3.83 – 3.52 ————————— 3.13 -3.89 71.1 3.15- 3.89 69.2
3″ 3.38 - 3.80 78.8 3.83 – 3.52 ————————— 3.13 -3.89 61.9 3.15- 3.89 61
4″ 3.38 - 3.80 69.1 3.83 – 3.52 ————————— 3.13 -3.89 56.6 3.15- 3.89 55.4
5″ 3.38 - 3.80 80.9 3.83 – 3.52 ————————— 3.13 -3.89 81.3 3.15- 3.89 60.8
6″ 3.38 - 3.80 59.8 3.83 – 3.52 ————————— 3.13 -3.89 82.0 3.15- 3.89 69.8
1‴ 4.78 [1H, d, (9.5)] 74.2 ————————— ————————— ————————— ————————— ————————— —————————
2‴ 3.38 - 3.80 71.9 ————————— ————————— ————————— ————————— ————————— —————————
3‴ 3.38 - 3.80 77.9 ————————— ————————— ————————— ————————— ————————— —————————
4‴ 3.38 - 3.80 70.6 ————————— ————————— ————————— ————————— ————————— —————————
5‴ 3.38 - 3.80 81.9 ————————— ————————— ————————— ————————— ————————— —————————
6‴ 3.38 - 3.80 61.3 ————————— ————————— ————————— ————————— ————————— —————————
Chemical shifts (δ) are in ppm and coupling constants (J em Hz) are given in parentheses.
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Figure 5 A graph showing the effects of acute treatment with
the crude extract of Erythrina falcata (CE) (A), buthanolic
fraction (BuF), the subtraction from BuF (B) and the flavonoidic
fraction (FfA and FfB) (C), as well as the negative (CS, Tween)
and positive control (Diazepam) treatments, on the acquisition
of fear memory as evaluated by one-trial, step-down inhibitory
avoidance (IA). The values for step-down latency are expressed as
the mean values (±SEM). *P < 0.05, **P < 0.01 and ***P < 0.001,
according to ANOVA followed by the Bonferroni’s Multiple Comparison
Test. ###P < 0.001, comparasion between Training and Test, according
to ANOVA followed by the Bonferroni’s Multiple Comparison Test. The
drugs and vehicle were administered at 30 min prior to the training
sessions using the flavonoidic fractions (FfA and FfB). No drugs were
administered during the test.
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http://www.biomedcentral.com/1472-6882/14/288was isolated as white crystals, and its 1H NMR spectrum
(Table 1) included signals at δ 6.75 (singlet) due to H-3,
signals at δ 6.92 (d, J = 8.0Hz) for H-3′/H-5′, δ 7.92 (d, J =
8.0Hz) for H-2′/H-6′, and the presence of the OMe, which
was confirmed by a singlet at δ 3.89 (4H’). The broad sing-
let at δ 13.54 was attributed to the -OH groups, which form
hydrogen bonds. The presence of an anomeric proton at δ
4.59 (d, J = 9.5 Hz; H-1″) attached to carbon at δ 123.06
suggested that compound 4 is C-glucoside flavone. The
sugar linkages to the aglycone were considered to be at
the C-6 positions, due to the presence of a quaternary
C-6- signal at δ 93.4. Comparing the spectroscopic data
of compound 5 with published spectra [42] confirmed its
identity as 6-C-glycoside-diosmetin (C22H20O10).
Compound 6 (λmax = 305, 265 nm, Figure 3C6) exhib-
ited a [M-H]− at m/z 269 and MS2 ions at m/z 225
([0,4X]−; [M-H]− -46) and m/z 241([0,4X]−; [M-H]− -28)
(Figure 4F). This compound was identified as 4′, 5, 7-
trihydroxyflavone, which is commonly known as api-
genin (C15H10O5).
Analysis of the data obtained by HPLC-ESI-MSn re-
vealed that vitexin, isovitexin and 6-C-glycoside-dios-
metin are present within the flavonoidic fraction FfA,
and furthermore, that all of the flavones identified were
present in the FfB.
The identification of vitexin and isovitexin was sup-
ported by the co-injection of the standards and CE. The
isolated substances (i.e., vicenin-2, vitexin, isovitexin and
6-C-glycoside-diosmetin) were quantified by HPLC and
yours content in the crude extract CE were 0.47 ± 0.24;
0.29 ± 0.15; 0.25 ± 0.06 and 0.20 ± 0.06 (mg/g ± SD).
The Crude Extract of E. falcata (CE) and Flavonoidic
Fractions improves the acquisition of fear memory
The effect of CE, (250 mg.Kg−1and 500 mg.Kg−1), and
the control treatment (4 mg.Kg−1 Diazepam and Tween®
80, n = 10/group) on inhibitory avoidance memory reten-
tion are shown in Figure 5A. The differences in mean
values (SEM) of step-down latencies between the Tr and
T1 sessions were considered as a measure of retention of
fear memory. No significant differences were observed
among the groups in terms of step-down latencies of
the training session (P > 0.05). There was a significant
difference in step-down latencies between the groups
(control × versus treated group) in the retention test
session [F (11,108) = 112.5, P < 0.0001], with the exception
of the CS group, in which no differences were observed in
the training session step-down latency values (P > 0.05).
Comparisons between the training and test session step-
down latencies revealed an effect on the acquisition of
memory for the controls and CE groups (P < 0.0001), with
the exception of the CS group (P > 0.05). The analyses of
the mean step-down latency values for each group in the
T1 period revealed that the CE-treated rats, at both doses,exhibited an increase in mean latency compared to the
CS group (P < 0.0001), Tween® group (P < 0.0001) and
Diazepam (P < 0.0001). Rats treated with Diazepam
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http://www.biomedcentral.com/1472-6882/14/288exhibited reduced latencies compared to the Tween®
group (P < 0.0001). In summary, treatment with CE im-
proved the acquisition of fear memory during the T1
session. Conversely, Diazepam decreased the retention
latency values of the T1 session compared to the Tween®
and CE groups.
The mean step-down latency values of the Tr and T1
session animals treated with 145 mg.Kg−1BuF, sub-
fractions of BuF (20 mg.Kg−1 BuF1, 16 mg.Kg−1 BuF2,
21 mg.Kg−1 BuF3, 45 mg.Kg−1 BuF4, 13 mg.Kg−1 BuF5
or 27 mg.Kg−1 BuF6) and the values of the corresponding
control animals (Tween®) prior to the training session are
shown in Figure 5B. There were no significant differences
among the groups in terms of step-down latencies of the
training session (P > 0.05) according to one-way ANOVA.
A significant difference was observed between the groups
(Tween® × treated group) of the T1 session [F(15,139) =
110.3, P < 0.0001]. Comparisons between the training and
test sessions revealed an effect on the acquisition of mem-
ory for the groups treated with BuF and the subfractions
(P < 0.0001), except for the BuF5-treated group (P > 0.05).
Analyses of groups in the T1 session revealed a significant
increase in mean step-down latencies for the groups
treated with 145 mg.Kg−1BuF, 21 mg.Kg−1BuF3 or 45 mg.
Kg−1BuF4 compared to those treated with Tween®, BuF1,
BuF2, BuF5 and BuF6 (P < 0.0001). Rats treated with 20 mg.
Kg−1BuF1, 16 mg.Kg−1BuF2 and 27 mg.Kg−1BuF5, exhib-
ited significantly shorter step-down latencies than those
treated with Tween®, BuF, BuF3 and BuF4 (P < 0.0001). No
differences in values were observed in the BuF6 and
Tween® groups (P > 0.05).
In summary, treatment with 145 mg.Kg−1BuF, 21 mg.
Kg−1BuF3 and 45 mg.Kg−1 BuF4 improved the acquisi-
tion of conditioned fear.
Shown in Figure 5C are the step-down latency values
of the animals treated with vicenin-2 (0.1, 0.3, 1.0 or
10.0 mg.Kg−1), vitexin (0.1 or 0.25 mg.Kg−1), isovitexin
(0.1 mg.Kg−1 or 0.25 mg.Kg−1), 0.1 mg.Kg−1 6-C-glyco-
side-diosmetin, 0.65 mg.Kg−1 FfB or 0.9 mg.Kg−1 FfA in
the Training (Tr) and Test (T1) sessions. There were no
significant differences among the groups in terms step-
down latencies in the training session (P > 0.05), as indi-
cated by One-way ANOVA. Comparisons of both training
and test sessions revealed a significant effect on step-
down latencies in terms of the acquisition of memory for
the groups treated with Tween®, vitexin, isovitexin, 6-C-
glycoside-diosmetin, FfA, FfB (P < 0.0001) or 0.3 mg.Kg−1
vicenin-2 (P < 0.05). No differences were observed in the
groups treated with vicenin-2 (0.1, 1.0 or 10 mg.Kg−1) upon
comparison of the Tr and T1 sessions. One-way ANOVA
revealed a significant effect on all of the groups treated in
the T1 session [F (24,225) = 296.4, P < 0.0001]. The retention
of step-down latencies of the groups treated with 0.25 mg.
Kg−1 vitexin, isovitexin, 6-C-glycoside-diosmetin, FfA orFfB were significantly increased compared to those of
Tween® and vicenin-2 and 0.1 mg.Kg−1 vitexin (P < 0.0001)
in T1 session. The rats treated with 0.3 mg.Kg−1 vicenin-2
and 0.1 mg.Kg−1 vitexin (P < 0.0001) exhibited significantly
reduced step-down latencies compared to those treated
with Tween® and 0.25 mg.Kg−1 vitexin, isovitexin, 6-C-
glycoside-diosmetin, FfA or FfB. In summary, treatment
with flavonoidic fractions, 0.25 mg.Kg−1 vitexin, isovitexin
and 6-C-glycoside-diosmetin improved the acquisition of
fear memory in the T1 session. Conversely, treatment
with 0.3 mg.Kg−1 vicenin-2 and 0.1 mg.Kg−1 vitexin
decreased retention latency in the T1 session compared
to treatment with Tween® and flavonoidic fractions,
0.25 mg.Kg−1 vitexin, isovitexin and 6-C-glycoside-dios-
metin groups. Nevertheless, the rats subjected to treat-
ments with vicenin-2 (0.1, 1.0 or 10.0 mg.Kg−1) exhibited
impaired fear memory when evaluated in T1.
Treatment with the Crude Extract of E. falcata (CE) or
Flavonoidic Fractions resulted in significant retention of
fear memory without impairing the extinction of fear
memory
Shown in Figure 6A are the values for retention of
fear memory as evaluated by the dL-mean (Test-Tr
latency) test of the groups treated with Tween®, 4 mg.
Kg−1 Diazepam and CE (250 mg.Kg−1 or 500 mg.Kg−1) in
the acquisition (T1) and extinction sessions (T2-T5).
Two-way ANOVA revealed significant effects of the treat-
ments [F (5,54) = 102.8, P < 0.0001], sessions [F (4,216) =
276.7, P < 0.0001] and significant treatment × session
interaction [F (20,216) = 27.20, P < 0.0001]. Analysis of the
groups on the 4th day (T2) revealed significant differences
in terms of the dL-mean for group treated with 250 mg.
Kg−1 CE (dL = 116.22 ± 6.93, P < 0.001) or 500 mg.Kg−1
CE (dL = 127.33 ± 8.48, P < 0.001) when compared to those
treated with Tween® (dL = 39.7 ± 4.83), CS (dL = 3.9 ± 0.80)
or Diazepam (dL = 32.0 ± 4.64) groups. No differences were
observed when the Diazepam group was compared to the
Tween® group (P > 0.05), but we had observed differences
in relation to CS group (P < 0.0001). On the 5th day (T3),
no significant differences were observed in terms of
dL-mean values for the groups treated with Diazepam
(dL = 18.30 ± 2.79, P > 0.05), 250 mg.Kg−1 CE (dL = 28.55 ±
4.15, P > 0.05) or 500 mg.Kg−1 CE (dL = 29.11 ± 6.91,
P > 0.05) compared to the control-treated groups (Tween®,
dL = 18.5 ± 5.04 and CS, dL = 3.8 ± 0.54). The analysis of
step-down latency on the 10th day after training (T4)
revealed that all of the groups exhibited mean dL values of
approximately 15 s (Diazepam, dL = 17.6 ± 2.13; 250 mg.
Kg−1 CE; DL = 13.55 ± 6.00, 500 mg.Kg−1 CE dL = 16.44 ±
4.55), except CS group (dL = 4.3 ± 0.95 (P < 0.001). Here,
no differences were observed among the groups (P > 0.05).
All of the animals tested on the 21st day after training
(T5) exhibited extinction of fear memory as evaluated in
Figure 6 A graph showing the effects of acute treatment with
the crude extract of Erythrina falcate (CE) (A), buthanolic
fraction (BUF), subfraction from BuF (B) and the flavonoidic
fractions (FfA and FfB) (C) on the acquisition and extinction of
fear memory as evaluated by one-trial, step-down inhibitory
avoidance (IA). The animals were subjected to five retention
sessions (T1-T5) of IA tasks. The values of the step-down latencies
are expressed as the as mean differences of the latencies between
Training and Test sessions (dL = mean ± EPM). *P < 0.05, **P < 0.01
and ***P < 0.001. No footshock was administered during the test
sessions. The interval between T1, T2 and T3 was 24 h. T4 and T5
comprised 240- and 480-h intervals, respectively, after training. No
drugs were administered during the test sessions. Two-way ANOVA
was used to consider the two fixed factors (group and trial) and one
random factor (rat). Repeated measures were employed for the
intragroup comparison of the retention test data (CS presentation).
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not acquire fear-conditioned memory. Differences were
observed among the groups treated with 250 mg.Kg−1 CE
(dL = 38.7 ± 3.16) or 500 mg.Kg−1 CE (dL = 36.44 ± 2.21)
compared to those treated with Diazepam (dL = 11.5 ±2.16), CS (dL = 3.6 ± 1.24) or Tween® (dL = 15.5 ± 3.04)
(P < 0.001). Intragroup comparisons revealed that all
of the groups exhibited significantly decreased dL-
mean values in the T2 session compared to the T1 session
(P < 0.0001). Rats treated with the both doses of CE ex-
hibited spontaneous recoveries in the T2 session and
decreased dL-mean values in the T3 - T5 sessions com-
pared to the T2 (P < 0.0001) and T1 (P < 0.0001) sessions.
No differences were observed in dL-mean values of the
Tween®, Diazepam and CS-treated groups in the T3 - T5
sessions (P > 0.05). In summary, every group acquired
conditioned fear. Nonetheless, the CE groups exhibited
significant dL-mean values during the T2 extinction
session.
Shown in Figure 6B are values of retention of fear
memory as evaluated by the dL-mean test of the groups
treated with of 145 mg. Kg−1BuF, subfractions of BuF
(20 mg.Kg−1BuF1, 16 mg.Kg−1BuF2, 21 mg.Kg−1BuF3,
45 mg.Kg−1 BuF4, 13 mg.Kg−1BuF5 or 27 mg.Kg−1BuF6)
and Tween® in the acquisition (T1) and extinction ses-
sions (T2-T5). Two-way ANOVA revealed a significant
effect of treatment [F (7,63) = 72.44, P < 0.0001], sessions
[F (4,36) = 71.56, P < 0.0001] and of significant interaction
of treatment x sessions [F (28,252) = 5.475, P < 0.0001].
Significant differences in the dL-mean values were ob-
served on the 4th day (T2) for the groups treated with
BuF (dL = 201.96 ± 22.92, P < 0.0001), BuF3 (dL = 278 ±
1.45), BuF4 (dL = 161.1 ± 21.23, P < 0.0001) or BuF6
(dL = 112.5 ± 24.80, P < 0.001) compared to the group
treated with Tween® (dL = 39.7 ± 4.83). However, no
differences were observed among the groups treated
with BuF1 (dL = 34.5 ± 11.94, P > 0.05), BuF2 (dL = 30.1 ±
6.71, P > 0.05), or BuF5 (dL = 14.4 ± 2.31, P > 0.05). On the
5th day (T3), there were significant differences in the
long-term memory retention of the group treated with
Tween® (dL = 18.5 ± 5.04) at 72 h after training compared
to the groups treated with BuF (dL-mean: 96.6.1 ± 16.98,
P < 0.0001), BuF3 (dL = 239.77 ± 24.58, P < 0.0001) of
BuF4 (dL = 155.2 ± 19.17, P < 0.0001), which exhibited
increased step-down latencies. However, no significant
differences were observed in the groups treated with
BuF1 (dL = 21.75 ± 6.76, P > 0.05), BuF2 (dL = 9.8 ± 1.97,
P > 0.05), BuF5 (dL = 13.4 ± 4.70, P > 0.05) or BuF6 (dL =
28.4 ± 7.09, P > 0.05). These groups exhibited impaired
acquisition of fear memory. The analysis of the data
from the 10th day after training (T4) revealed signifi-
cant differences in the dL-mean values of the groups
treated with BuF (dL = 159.7 ± 11.93, P > 0.0001), BuF3
(dL = 199.4 ± 17.34, P > 0.0001), or BuF4 (dL = 178.2 ±
36.28, P > 0.0001). These groups exhibited increased step-
down latencies compared to the groups treated with
Tween® (dL = 20.5 ± 5.04), BuF1 (dL = 14.12 ± 3.87), BuF2
(dL = 19.7 ± 3.70), BuF5 (dL = 15.80 ± 3.56) and BuF6
(dL = 7.96 ± 1.71). Significant differences in the dL-mean
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tested after training and treatment with BuF (dL = 87.2 ±
12.80, P < 0.0001), BuF3 (dL = 153.1 ± 22.01, P < 0.0001) or
BuF4 (dL = 64.3 ± 6.05, P < 0.05) compared to the groups
treated with Tween® (dL = 9.9 ± 1.1), BuF1 (dL = 3.62 ±
1.01, P > 0.05), BuF2 (dL = 6.2 ± 1.73, P > 0.05) or BuF6
(dL = 6.20 ± 1.93, P > 0.05). Treatment with BuF5 (dL =
6.90 ± 1.96) did not influence the extinction of fear mem-
ory, because the animals did not acquire fear memory.
Intragroup comparisons revealed that BuF1 and BuF6
groups exhibited decreased dL-mean values in the T2-T5
sessions compared to the T1 session (P < 0.001). No differ-
ences in dL-mean values were observed in the groups
treated with BuF5 when the T1 and T5 sessions were
compared (P > 0.05). The groups treated with BuF, BuF3
or BuF4 exhibited decreased dL-mean values in the T2- T5
sessions compared to the T1 (P < 0.0001). In summary,
these data showed that fear memory was not attenuated by
repeated testing after treatment with BuF, BuF3 or BuF4,
resulting in significantly improved retention of fear mem-
ory when tested at 48, 72, 240 and 480 hours. These groups
were particularly resistant to extinction.
Shown in Figure 6C are the values for retention of fear
memory as evaluated by the dL-mean test of the groups
treated with Tween®, vicenin-2 (0.1, 0.3, 1.0 and 10.0 mg.
Kg−1), vitexin (0.1 or 0.25 mg.Kg−1), isovitexin (0.1 or
0.25 mg.Kg−1), 0.1 mg.Kg−1 6-C-glycoside-diosmetin,
0.65 mg.Kg−1 FfB and 0.9 mg.Kg−1 FfA. Two-way ANOVA
revealed a significant effect of treatment [F (11,107) =
129.7, P < 0.0001], sessions [F (4,428) = 450.0, P < 0.0001]
and the interaction of treatment x sessions [F (44,428) =
34.70, P < 0.0001]. Significant differences in the dL-mean
values were observed on the 4th day (T2) for the
groups treated with 0.25 mg.Kg−1vitexin (dL = 242 ± 22.89,
P < 0.0001), 0.1 mg.Kg−1 isovitexin (dL = 142.2 ± 7.0,
P < 0.0001), 0.25 mg.Kg−1 isovitexin (dL = 242.3 ± 5.29,
P < 0.0001), 6-C-glycoside-diosmetin (dL = 267.9 ± 17.12,
P < 0.0001), FfA (dL = 191.2 ± 25.69, P < 0.0001), and FfB
(dL = 185.9 ± 18.28, P < 0.0001) compared to the groups
treated with Tween® (dL = 39.7 ± 4.83), but no significant
differences were observed for any of the doses of vicenin-
2 (0.1, 0.3, 1.0 and 10.0 mg.Kg−1) and (0.1 mg.Kg−1vitexin
(P > 0.05). On the 5th day (T3), there were significant dif-
ferences between the group treated with 0.25 mg.Kg−1
vitexin (dL = 128.8 ± 20.13, P < 0.0001), 0.1 mg.Kg−1
isovitexin (dL = 76.5 ± 1.73, P < 0.0001), 0.25 mg.Kg−1
isovitexin (dL = 155.8 ± 6.08, P < 0.0001), 6-C-glycoside-dios-
metin (dL = 209.7 ± 21.65, P < 0.0001), FfA (dL = 136.9 ±
6.67, P < 0.0001), and FfB (dL = 163.3 ± 26.21, P < 0.0001)
compared to the groups treated with Tween® (dL = 18.5 ±
5.04), 0.1 mg.Kg−1vitexin (dL = 15.9 ± 2.20), 0.1 mg.
Kg−1vicenin-2 (dL = 2.4 ± 1.8), 0.3 mg.Kg−1vicenin-2
(dL = 18.44 ± 5.44), 1.0 mg.Kg−1vicenin-2 (dL = 12.4 ±
5.40) and 10.0 mg.Kg−1vicenin-2 (dL = 12.8 ± 6.34),indicating increased step-down latencies. No significant
differences in the dL-mean values were observed in the
groups treated with vicenin-2 (0.1, 1.0, 0.3 or 10.0 mg.
Kg−1) and 0.1 mg.Kg−1vitexin compared to the groups
treated with Tween® (P > 0.05), indicating these groups
exhibited reduced dL step-down latencies. The analysis of
these data from the 10th day after training (T4) revealed
no significant differences in dL-mean values compared to
groups treated with 0.1 mg.Kg−1 vitexin (dL = 13.7 ± 1.2,
P > 0.05), 0.3 mg.Kg−1 vicenin-2 (dL = 14.88 ± 5.92, P >
0.05), 1.0 mg.Kg−1 vicenin-2 (dL = 11.4 ± 4.63, P > 0.05),
10.0 mg.Kg−1 vicenin-2 (dL = 3.4 ± 1.54, P > 0.05),
0.65 mg.Kg−1 FfB (dL = 33.8 ± 6.67, P > 0.05) or 0.9 mg.
Kg−1 FfA (dL = 24.2 ± 2.96, P > 0.05) when compared with
Tween® (dL = 20.5 ± 1.1), but significant differences in the
dL-mean values were observed in the groups treated with
0.25 mg.Kg−1 vitexin (dL = 54.5 ± 2.52, P < 0.0001), 6-C-
glycoside-diosmetin (dL = 41.6 ± 6.59, P < 0.05), 0.1 mg.
Kg−1 isovitexin (dL = 57.9 ± 1.79, P < 0.05) or 0.25 mg.Kg−1
isovitexin (dL = 54.5 ± 4.03, P < 0.05) compared to the all
groups. No significant differences in the dL-mean values
were observed in animals tested on the 21st day after
training (T5) and treatment with 0.1 mg.Kg−1 vitexin
(dL = 14.7 ± 1.55, P > 0.05), 0.25 mg.Kg−1 vitexin (dL =
36.1 ± 2.20, P > 0.05), 0.1 mg.Kg−1 vicenin-2 (dL = 6.3 ±
1.84, P > 0.05), 0.3 mg.Kg−1 vicenin-2 (dL = 11.55 ± 2.90,
P > 0.05), 1.0 mg.Kg−1 vicenin-2 (dL = 19.8 ± 4.63, P > 0.05),
10.0 mg.Kg−1 vicenin-2 (dL = 2.2 ± 1.98, P > 0.05), 0.1 mg.
Kg−1 isovitexin (dL = 39.5 ± 2.00, P > 0.05), 0.25 mg.Kg−1
isovitexin (dL = 14.7 ± 2.00, P > 0.05), 0.1 mg.Kg−1 6-C-
glycoside-diosmetin (dL = 43.5 ± 5.71, P > 0.05), 0.65 mg.
Kg−1 FfB (dL = 31.7 ± 6.17, P > 0.05) or 0.9 mg.Kg−1 FfA
(dL = 24.1 ± 3.08, P > 0.05) compare to the group treated
with Tween® (dL = 9.9 ± 1.1). Intragroup comparisons re-
vealed that rats treated with isovitexin (0.1 or 0.25 mg.Kg−1)
exhibited a gradual decrease in the dL-mean values of the
T2 and T3 sessions compared to the T1 session (P <
0.0001). Significant differences in the dL-mean values were
observed on groups treated with 6-C-glycoside-diosmetin
in the T3 session compared to the T1 and T2 (P < 0.0001)
sessions. Rats treated with vitexin (0.1 or 0.25 mg.Kg−1) ex-
hibited a decreased in dL-mean values in the T2 session
compared to the T1 session (P < 0.0001). No differences in
dL-mean values were observed in the group treated with
vicenin-2 (0.1, 0.3, 1.0 or 10.0 mg.Kg−1) when comparing
values for the T1 - T5 sessions (P > 0.05). In sessions T4-
T5, all of the groups exhibited decreased dL-mean values
when compared to the T1, T2 and T3 sessions (P < 0.0001),
with the exception of the group treated with vicenin-2.
In summary, with the exception of the group treated
with vicenin-2 (0.1, 1.0 and 10 mg.Kg−1) every groups
exhibited the acquisition and extinction of fear memory.
However, treatment with vitexin (0.1 or 0.25 mg.Kg−1),
isovitexin (0.1 or 0.25 mg.Kg−1), and 0.1 mg.Kg−16-C-
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ory, as indicated in the T1-T3, but did not prevent the
extinction of fear memory.
Discussion
Phytochemical analysis has demonstrated that most of
the secondary metabolites characterized in our study are
flavones, and for the first time, are identified in the plant
Erythrina falcata. Furthermore, monitored fractionation
using a one-trial step-down inhibitory avoidance task
(IA) showed that the CE, buthanolic total fraction (BuF),
subfractions and flavonoidic fractions modulated the ac-
quisition and extinction of fear memory. Rats treated with
0.25 mg.Kg−1 vitexin, isovitexin (0.1 or 0.25 mg.Kg−1) and
6-C-glycoside-diosmetin and FfA or FfB exhibited en-
hanced retention of fear memory, as indicated in T1 to
T3. In addition, the treatment with BuF, BuF3 and BuF4,
resulted in particular resistance to extinction.
The molecular structure of the secondary metabolites of
the crude extract of E. falcata
The use of hyphenated techniques has been employed to
characterize and identify flavonoids in natural products.
The power of combining separation technologies with
spectroscopic techniques has been extensively demon-
strated for both the quantitative and qualitative analysis
of unknown compounds in complex natural product
extracts or fractions. To obtain structural information
for the identification of the compounds present in a crude
sample, various modern hyphenated techniques have been
applied, including for example, GC-MS, LC-MS, and LC-
NMR. HPLC is the most widely used analytical separation
technique for the qualitative and quantitative determin-
ation of compounds in natural product extracts [43].
In this study, we used HPLC-ESI/MSn to structurally
characterize and identify the compounds present in
CE, because this technique facilitates the rapid screening
of crude natural product extracts or fractions for detailed
information, such as metabolic profiles, using a minimal
amount of material.
Flavonoids commonly exist as flavonoid O-glycosides,
in which one or more of the hydroxyl groups of the agly-
cone are bound to a sugar, forming a glycosidic O-C
bond. However, flavonoids can also exist as flavonoid
C-glycosides, in which glycosylation might occur directly
through the linkage of the sugar to the basic nucleus of
the flavonoid via a C-C bond [44-46].
According to our UV spectral profiles, the majority of
the CE compounds exhibit a predominance of flavones.
The UV spectra of flavones exhibited two strong absorp-
tion peaks that are commonly referred to as band I
(300–380 nm) and band II (240–280 nm). Band I is
associated with the presence of a cinnamoyl system
that involves ring B, whereas Band II is attributed toan A-ring with a benzoyl system. Substitutions on rings
A or B might produce hypsochromic or bathochromic
shifts of the absorption peaks, which are useful for clarify-
ing structures. In the flavone glycosides, O- and C- glyco-
sylation of ring A appears to elicit little-to-no effect on
their UV spectral profiles, but glycosylation of the ring B
induces shifts of band I to lower wavelengths (hypsochro-
mic shift), with this effect being increased for a resonant
position (4′) than for a non-resonant position (3′) [33].
Flavones C-glycosides exhibit the typical UV spectra of fla-
vones (band I and band II of similar intensities). These
findings support the spectral profile of compounds 1–6.
The UV spectral profiles that we obtained from the crude
extract and active fractions exhibited two main absorption
peaks of approximately 260 and 331 nm, which are typical
of flavones [33].
Tandem mass spectrometric fragmentation (ESI-MS/
MS) has been extensively used to characterize flavonoids.
The combinations of both ionization modes (positive and
negative) in MS1 full scan mode yields enhanced certainty
in terms of determining the molecular mass. The negative
ion mode provides the optimal sensitivity and results in
fragmentation, making it the most suitable for inferring
the molecular mass of separated flavonoids [47].
Our HPLC-ESI/MS study permitted identified most of
the flavonoids, presents in CE of in the E. falcata. The
fragmentation pathways demonstrated the presence the
two flavones di-C-glycosides (compound 1 and 2), three
flavones mono-C-glycosides (compound 3, 4 and 5). The
fragmentation data obtained from vicenin-2 (1) at m/z
593[29,47-49], vicenin-1 (2) at m/z 563 [36], vitexin (3)
at m/z 431 [29,47,50], isovitexin (4) at m/z 431 [36,48,50],
6-C-glycoside-diosmetin (5) at m/z 461 [47,49,51,52] and
apigenin (6) at m/z 269 [53] are consistent with the frag-
mentation data for C-glycosides that have been previously
described in literature. The vicenin-1 (2) and vicenin-2 (1)
were found in the first time in E. falcata. Vicenin-2 has
been described in the other Erythrina species including
E. indica [54] and E. caffra [35]. Both compounds were
found in the Passiflora incarnata [55]. Vitexin and iso-
vitexin have been described in other Erythrina species
such as E. indica [54] and E. caffra [35]. This study, how-
ever, is the first report of such compounds in E. falcata.
In addition, these compounds can also be found as
active components of extracts derived from Passiflora
incarnata [55]. Notably, this is the first description of
6-C-glycoside-diosmetin in E. falcata plants and in the
Erythrina genus.
For the first time, our results demonstrated that pre-
dominant secondary metabolites found in crude dry
extracts of Erythrina falcata belong to a subclass of
flavone C-glycosides and might represent a potential
marker of this extract. According to our quantitative
analyses vicenin-2, vitexin and isovitexin represent the
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glycoside-diosmetin was identified as the least abundant
constituent. Furthermore, our bioactivity-guided study de-
monstrated that these compounds, which were present
in both flavonoidic fractions, are attributable for the
biological effects observed in this study.
Monitored fractionation study in the acquisition and
extinction of fear memory
Our main finding was that treatment with CE, BuF,
BuF3 and BuF4, vitexin, isovitexin, 6-C-glycoside-dios-
metin and flavonoidic fractions (FfA and FfB) can im-
prove the acquisition of fear memory. These flavone
mono-C-glycosides, both doses of isovitexin, 0.25 mg.Kg−1
vitexin, 6-C-glycoside-diosmetin and both flavonoidic
fractions induced retention of extinction of fear. Further-
more, rats treated with BuF, BuF3 and BuF4 were resistant
to extinction. Together, these findings suggest that com-
ponents present in the butanolic fraction (BuF), also found
in the subfractions 3 and 4 (BuF3 and BuF4), can modu-
late the fear extinction. This hypothesis is established in
data from treatments with CE or isolated flavones mono-
C-glycosides, which acquired the fear extinction memory.
In this sense, the interaction among compounds pre-
sents in the BuF as well as subfractions BuF3 and
BuF4 can modulate fear memory acquisition and possibly
their consolidation as well. This raises the question of
the adaptive value of flavones in memory formation.
To better understand our findings, a current descrip-
tion concerning the role of flavonoids in memory forma-
tion is required.
Converging evidence over the last few decades has
shown that extracts of flavonoid-rich plant or flavonoid
molecules have been the focus of numerous researches
as potent modulators of memory formation and cogni-
tion. Recent evidence has indicated that the consump-
tion of flavonoid-rich plants or/and foods, extracts, and
purified flavonoids are correlated with improved mem-
ory, which prevents age-related spatial learning deficit in
mice [56] or improves fear memory acquisition [2]. Add-
itionally, it has been suggested that improved memory
flavonoid-induced seems attributable to their ability in
modulating different neurotransmitter systems.
Generally, flavonoids act as modulators of the GABAA
receptors [57-59]. However, they can also modulate
others receptors that are important for neural plasticity
(e.g., TrKB and NMDA receptors) [60-62]. One way they
act is by regulating proteins such as mitogen-activated
protein kinase (MAPK), phosphoinositide 3-kinase (PI3
kinase)/Akt signalling cascade [22] and cAMP response
element-binding protein (CREB) [1,2].
The ability of various flavones to modulate the GABAA
receptor is related with a pharmacophore model that was
previously proposed by Cook and Dekermendjian [63].The “diazepam-like” effects justify the use of diazepam as
a positive control in our work.
The pre-training administration benzodiazepine agon-
ist resulted in impaired acquisition of fear memory in
behavioral models such as inhibitory avoidance. Ours re-
sults, in combination with other published studies, con-
firms that treatment with diazepam impairs retention
test performance in conditioned fear tasks.
Likewise, treatment with flavone di-C-glycoside vicenin-
2, (0.1, 1.0 or 10.0 mg.Kg−1), impairs acquisition of con-
ditioned fear. Conversely, rats treated with 0.3 mg.Kg−1
vicenin-2 and 0.1 mg.Kg−1 vitexin had acquisition of fear
memory, but they exhibited slower latency retention in
the IA tasks. These data suggest that the flavones from CE
in IA may modulate different neurochemical systems.
Interestingly, the flavone mono-C-glycoside identified
in our study is of the same class as 6, 2′dihydroxyflavone
(DHF). A functional electrophysiological study has pre-
viously shown that DHF decreased GABA-induced cur-
rents in α1β3γ2, α2β3γ2 and α5β3γ2 subunits but not in
the α3β3γ2 subunit of the GABAA receptors [64]. The
authors also demonstrated that DHF enhanced cognitive
performance in the step-through passive avoidance test
and elicited an anxiogenic-like effect when evaluated in
the elevated plus-maze test, thus functioning as a partial
inverse agonist-like modulator of the GABAA receptor
[64]. Thus, we hypothesize that flavone mono-C-glyco-
sides, as well as FfA and FfB might function as partial
inverse agonist-like modulators of the GABAA receptor.
However, further studies are required to determine of ac-
tion of these bioactive molecules on GABAA receptor and
to understand their molecular and functional action as
modulators of acquisition and extinction of fear memory.
FfA contains three flavone mono-C-glycosides (vitexin,
isovitexin and 6-C-glycoside-diosmetin) and FfB contains
all of the flavonoids identified in this study. Both of the
flavonoidic fractions improved the acquisition fear
memory, consistent with our findings of improved fear
conditioned memory in short-term [2] and long-term [1]
treatment groups that were administered a standardized,
flavonoid-rich extract of Ginkgo biloba (EGb). Other
studies have demonstrated beneficial effects of Ginkgo
biloba extract on memory [65-67]. A beneficial effect of
flavonoid-rich blueberry supplements on the acquisition
of spatial memory has also been described [18]. These
findings, in combination with our data regarding treat-
ment with the flavonoidic fractions, confirm the benefi-
cial effects elicited on fear memory. Thus, the presence
of vicenin-2 in FfB and CE did not impair retention test
performance in the conditioned fear tasks.
Repeated testing for inhibitory avoidance every 24 h
after training resulted in significant retention of fear mem-
ory in the groups treated with CE, vitexin, isovitexin and
6-C-glycoside-diosmetin or both flavonoidic fractions.
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ticularly resistant to extinction.
Substances that facilitate GABA transmission have been
shown to interfere with the acquisition and consolidation
of fear memory, which can be blocked by extinction when
administered prior to the extinction training [68]. This
evidence suggests that increasing GABA transmission can
impair extinction retention, as observed with the BuF,
BuF3 and BuF4 treatments. Conversely, the administration
of FG7142 (N-methyl-β-carboline-3-carboxamide), a
nonselective inverse GABAA agonist, to rats prior to
extinction training of contextual fear memory, delayed
the extinction and increased the levels of freezing across
the course of the session test compared with the control
treatment [69]. This inverse agonist decreased GABA
transmission when administered prior to extinction train-
ing and impaired extinction retention [69]. Taken together,
we infer that substances that are inverse agonists of the
GABA receptor do not cause retention extinction, but
rather, increased the retention of memory by 72 h after
training. This effect was elicited by all of the mono-C-
glycosides flavones, FfA and FfB.
Extinction is regarded as a form of new learning that
involves the formation of a new association between the
CS and non-US. The fear responses exhibited in the pres-
ence of CS are reduced (i.e., extinguished) over the course
of exposure to CS alone (within- session extinction) [68].
This reduced response was not observed for BuF,
BuF3 or BuF4, indicating that these compounds prevent
extinction.
Despite the evidence from our studies, few studies
have examined the effects of flavonoid-rich extracts and
pure flavonoids on the extinction of fear memory. For
example, Andero et al. [70] demonstrated that 7,8-DHF
might represent an excellent reagent for elucidating the
effects of TrkB activation in learning and memory para-
digms and might enhance extinction in wild-type mice.
That is, 7,8-DHF can “rescue” a deficit in the extinction
of conditioned fear found in animals exhibiting a prior
history of a single traumatic stress exposure [70]. The
authors concluded that 7,8-DHF might potentially be
used for the treatment of reversing learning and extinction
deficits associated with psychopathology, and furthermore,
might serve as a useful adjuvant treatment for anxiety dis-
orders that are responsive to behavioral treatments using
the extinction process.
These studies sustain our hypothesis that acute treat-
ment with flavones (vitexin, isovitexin and 6-C-glycoside-
diosmetin) can elicit effects similar to those of partial
inverse agonists of GABAA receptors and can enhance
cognitive performance in IA acquisition, without causing
the cognitive deficit associated with the administration of
benzodiazepines. In addition, according with our chemical
data, these flavones are also found in the flavonoidicfractions (FfA and FfB) and CE which improved fear mem-
ory. Our data suggest that vitexin, isovitexin, 6-C-glycoside-
diosmetin and flavonoidic fractions (FfA and FfB) might
serve as a useful adjuvant treatment for memory deficits.
Conclusions
The most important contribution of this work is the
seminal characterization and identification of the com-
pounds derived from E. falcata plants. Our study has
revealed that this plant is rich source of flavones. In
addition, our monitored fractionation study provides
strong evidence for the pharmacological properties of
pure flavones including vitexin, isovitexin and 6-C-
glycoside-diosmetin, which can enhance the acquisition
of fear memory without preventing its extinction. These
flavonoids might be responsible for the effects elicited
CE, FfA and FfB. However, further studies are necessary
to determine the mode of action of the flavonoidic frac-
tions and the purified flavones (vitexin, isovitexin and
diosmetin-6-C-glucoside) in fear memory. Finally, these
data suggest that isolated flavones or flavonoidic fractions
can provide novel therapeutic approaches that might be
used for the treatment of cognitive deficits.
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